Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274540 | 0.89 | PRKCA (0.55) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL394439 | 0.89 | PRKCA (0.57) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL393733 | 0.88 | PRKCA (0.51) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL2957655 | 0.88 | PRKCA (0.70) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL3088711 | 0.88 | PRKCA (0.70) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL393188 | 0.84 | PRKCA (0.52) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL396060 | 0.84 | PRKCA (0.68) | PRKCAMMP12SCN9ANR1I2SLC22A12 | |
| SCHEMBL2274527 | 0.84 | PRKCA (0.61) | PRKCAMMP12SCN9ANR1I2CYP3A4 | |
| SCHEMBL2273255 | 0.84 | PRKCA (0.54) | PRKCAMMP12SCN9ANR1I2KMO | |
| SCHEMBL391578 | 0.83 | PRKCA (0.66) | PRKCAMMP12SCN9ANR1I2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-7989438-B2 | Therapeutic compounds | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-02 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | PRKCA 4625/4885MMP12 2333/4885SCN9A 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.